303 related articles for article (PubMed ID: 30450291)
1. Malignant peritoneal mesothelioma: a review.
Broeckx G; Pauwels P
Transl Lung Cancer Res; 2018 Oct; 7(5):537-542. PubMed ID: 30450291
[TBL] [Abstract][Full Text] [Related]
2. Malignant peritoneal mesothelioma: a review.
Kim J; Bhagwandin S; Labow DM
Ann Transl Med; 2017 Jun; 5(11):236. PubMed ID: 28706904
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Malignant Peritoneal Mesothelioma.
Levý M; Boublíková L; Büchler T; Šimša J
Klin Onkol; 2019; 32(5):333-337. PubMed ID: 31610664
[TBL] [Abstract][Full Text] [Related]
4. Malignant Peritoneal Mesothelioma as a Rare Cause of Dyspeptic Complaints and Ascites: A Diagnostic Challenge.
Marques de Sousa S; Pereira F; Duarte M; Marques M; Vázquez D; Marques C
GE Port J Gastroenterol; 2020 Apr; 27(3):197-202. PubMed ID: 32509926
[TBL] [Abstract][Full Text] [Related]
5. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.
Tada A; Minami T; Kitai H; Higashiguchi Y; Tokuda M; Higashiyama T; Negi Y; Horio D; Nakajima Y; Otsuki T; Mikami K; Takahashi R; Nakamura A; Kitajima K; Ohmuraya M; Kuribayashi K; Kijima T
Lung Cancer; 2023 Jun; 180():107219. PubMed ID: 37146474
[TBL] [Abstract][Full Text] [Related]
7. Malignant peritoneal mesothelioma literature review: past, present, and future.
Gregory SN; Sarvestani AL; Blakely AM
Dig Med Res; 2022 Jun; 5():. PubMed ID: 36061260
[TBL] [Abstract][Full Text] [Related]
8. Advances in malignant peritoneal mesothelioma.
Cao S; Jin S; Cao J; Shen J; Hu J; Che D; Pan B; Zhang J; He X; Ding D; Gu F; Yu Y
Int J Colorectal Dis; 2015 Jan; 30(1):1-10. PubMed ID: 25331029
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma.
Sugarbaker PH
Int J Surg Protoc; 2023 Dec; 27(3):108-117. PubMed ID: 38046900
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.
Lin RC; Kirschner MB; Cheng YY; van Zandwijk N; Reid G
Genom Data; 2016 Sep; 9():44-9. PubMed ID: 27408810
[TBL] [Abstract][Full Text] [Related]
11. Value of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy to treat malignant peritoneal mesothelioma.
Wang T; Li H; Ye B; Zhang D
Am J Transl Res; 2021; 13(9):10712-10720. PubMed ID: 34650746
[TBL] [Abstract][Full Text] [Related]
12. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.
Boussios S; Moschetta M; Karathanasi A; Tsiouris AK; Kanellos FS; Tatsi K; Katsanos KH; Christodoulou DK
Ann Gastroenterol; 2018; 31(6):659-669. PubMed ID: 30386115
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations.
Enomoto LM; Shen P; Levine EA; Votanopoulos KI
Cancer Manag Res; 2019; 11():4231-4241. PubMed ID: 31190990
[TBL] [Abstract][Full Text] [Related]
14. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
Sugarbaker PH; Chang D
Eur J Surg Oncol; 2017 Jul; 43(7):1228-1235. PubMed ID: 28189456
[TBL] [Abstract][Full Text] [Related]
15. Malignant Peritoneal Mesothelioma: A Case Report.
Sousa B; Silva J; Monteiro N; Romano M; Araújo E
Cureus; 2023 Aug; 15(8):e42902. PubMed ID: 37664365
[TBL] [Abstract][Full Text] [Related]
16. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal mesothelioma.
Hesdorffer ME; Chabot J; DeRosa C; Taub R
Curr Treat Options Oncol; 2008 Jun; 9(2-3):180-90. PubMed ID: 18841478
[TBL] [Abstract][Full Text] [Related]
18. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
Zhang W; Wu X; Wu L; Zhang W; Zhao X
Ann Transl Med; 2015 Aug; 3(13):182. PubMed ID: 26366399
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date.
Levin PA; Dowell JE
Onco Targets Ther; 2017; 10():2057-2066. PubMed ID: 28435296
[TBL] [Abstract][Full Text] [Related]
20. Update on the management of malignant peritoneal mesothelioma.
Sugarbaker PH
Transl Lung Cancer Res; 2018 Oct; 7(5):599-608. PubMed ID: 30450299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
